Last reviewed · How we verify

NCT07012759

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

Recruiting now Last updated 5 March 2026
What this trial tests

trial testing biomarkers in Biomarkers in 100 participants. Currently enrolling.

Timeline
10 June 2025
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorFu Jen Catholic University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date10 June 2025
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Fu Jen Catholic University

Who can join

18 and older, any sex, with Biomarkers or Lung Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of biomarkers

Trials testing the same drug.

Other recruiting trials for Biomarkers

Currently open trials in the same condition.

Other Fu Jen Catholic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07012759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing